A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Type2 Diabetes
Diabetes Mellitus
Diabetes Mellitus, Type 2
T2D
T2DM (Type 2 Diabetes Mellitus)
Glucose Metabolism Disorders
Endocrine System Diseases
Metabolic Disease

Interventions

DRUG: Tirzepatide Dose 1
DRUG: Tirzepatide Dose 2
DRUG: Placebo

Sponsor

Eli Lilly and Company